Insider Selling: bluebird bio Inc (BLUE) Insider Sells 3,000 Shares of Stock

bluebird bio Inc (NASDAQ:BLUE) insider David Davidson sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, April 12th. The shares were sold at an average price of $180.17, for a total value of $540,510.00. Following the completion of the sale, the insider now owns 27,905 shares of the company’s stock, valued at $5,027,643.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

David Davidson also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Monday, April 2nd, David Davidson sold 22,000 shares of bluebird bio stock. The shares were sold at an average price of $167.52, for a total value of $3,685,440.00.
  • On Friday, February 2nd, David Davidson sold 4,000 shares of bluebird bio stock. The shares were sold at an average price of $202.36, for a total value of $809,440.00.

Shares of BLUE traded down $2.85 during trading hours on Monday, reaching $170.20. The stock had a trading volume of 443,914 shares, compared to its average volume of 863,239. bluebird bio Inc has a 12 month low of $74.45 and a 12 month high of $236.17. The stock has a market capitalization of $8,649.65, a price-to-earnings ratio of -22.08 and a beta of 2.16.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.84). bluebird bio had a negative net margin of 947.42% and a negative return on equity of 28.09%. The firm had revenue of $4.17 million during the quarter, compared to the consensus estimate of $7.11 million. During the same quarter in the previous year, the company posted ($1.88) earnings per share. The firm’s revenue was up 169.0% on a year-over-year basis. research analysts anticipate that bluebird bio Inc will post -8.39 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in BLUE. Great West Life Assurance Co. Can lifted its stake in shares of bluebird bio by 22.7% in the 3rd quarter. Great West Life Assurance Co. Can now owns 5,531 shares of the biotechnology company’s stock valued at $778,000 after acquiring an additional 1,022 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of bluebird bio by 32.4% in the 3rd quarter. Legal & General Group Plc now owns 20,076 shares of the biotechnology company’s stock valued at $2,762,000 after acquiring an additional 4,912 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of bluebird bio by 31.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 139,994 shares of the biotechnology company’s stock valued at $19,231,000 after acquiring an additional 33,805 shares during the last quarter. Stifel Financial Corp bought a new position in shares of bluebird bio in the 3rd quarter valued at $391,000. Finally, Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of bluebird bio by 454.2% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 813 shares during the last quarter.

Several equities research analysts recently issued reports on BLUE shares. Cantor Fitzgerald cut their price target on bluebird bio from $122.00 to $113.00 and set an “underweight” rating for the company in a research note on Thursday, February 22nd. ValuEngine upgraded bluebird bio from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. BidaskClub cut bluebird bio from a “hold” rating to a “sell” rating in a research note on Wednesday, April 4th. Morgan Stanley boosted their price target on bluebird bio from $152.00 to $209.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 21st. Finally, William Blair started coverage on bluebird bio in a research note on Monday, March 5th. They issued an “outperform” rating and a $242.00 price target for the company. Four investment analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the stock. bluebird bio currently has a consensus rating of “Hold” and an average target price of $195.20.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.chaffeybreeze.com/2018/04/16/insider-selling-bluebird-bio-inc-blue-insider-sells-3000-shares-of-stock.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply